Albuquerque, NM, March 31, 2014 --(PR.com
)-- Dr. Yoganathan is a SME in the areas of biomaterials and drug delivery - having collaborated and worked closely with thought-leaders in the field such as Dr. Robert Langer, Dr. Kazunori Kataoka, Dr. Michael V. Sefton and Dr. Christine Allen. He is an expert in manipulating material properties to promote cell adhesion and controlled release of excipients. Dr. Yoganathan has international experience in leading CMC-guided analysis of drug delivery systems. He has worked in R&D start-ups in North America, Asia and Australia - developing small molecule formulations for ovarian cancer, laryngeal cancer and ocular diseases. His work and analytical approach has successfully stabilized formulations and altered the delivery to attain sustained release for weeks both in vitro and in vivo.
While working at the Centre for Commercialization of Regenerative Medicine (CCRM), a Canadian Centre of Excellence for Commercialization Research, his technical expertise was relied upon to assess and dispense start-up funding. Here, he led a team of scientists and technicians to devise new biomaterial surfaces and devices to address issues in scale-up of bioprocesses and cell therapies for clinical trials. Dr. Yoganathan was awarded the competitive Elevate Industrial Postdoctoral Fellowship Award, a national fellowship where only 10% of applicants were successful. He currently serves as Editor for Mitacs, a Canadian national granting agency, responsible for dispensing millions to promote Canadian research and innovation.
Dr. Yoganathan’s research interests involve the use of material chemistry and pharmaceutical science to develop new biopolymers for drug delivery and tissue engineering applications. In the past he been professionally affiliated with the University of New South Wales, University of Toronto and Beijing University of Chemical Technology. He is an award-winning scientific writer, being recognized by a 2013 Canadian Online Publishing Award for his posts on the evolution of biomaterials, pathogen biosensors, biometrics and bioadhesion. "We are pleased to have him as part of the team," noted Dr. Sheldon K. Jordan.